Spectrum Pharma

Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of novel and targeted oncology therapies. Its product pipeline includes: Eflapegrastim, Poziotinib, and IGN002. The company was founded in December 1987 and is headquartered in Henderson, NV.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Spectrum Pharmaceuticals is a biopharmaceutical company that focuses on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus on oncology. It has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development.

Spectrum Pharmaceuticals (NASDAQ: SPPI ) stock is soaring higher on Tuesday thanks to an acquisition deal with Assertio (NASDAQ: ASRT ). This deal will have Assertio acquire all outstanding shares of SPPI stock.

Why Is Spectrum Pharmaceuticals (SPPI) Stock Up 35% Today?

-- Children aged 5 to 17 with autism are now eligible to enroll in the clinical trial of AB-2004, a gut targeted, molecular therapeutic -- -- Novel small molecule microbiome approach focused on gut-brain axis connection offers potential alternative to anti-psychotic treatments --

Axial Therapeutics Announces Age Expansion in Global Phase 2b Clinical Trial for Irritability Associated with Autism Spectrum Disorder (ASD)

Bright Green Corp

Chembio Diagnostics

Healthcare Triangle

Hepion Pharmaceuticals Inc

Hillstream Biopharma

Magenta Therapeutics Inc

Sigilon Therapeutics

The healthcare sector has more high return generating companies than many other sectors.

10 Best-Performing Penny Stocks in the Health Care Sector

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI ) Q4 2022 Earnings Conference Call March 22, 2023 8:30 AM ET Company Participants Thomas Riga - President and Chief Executive Officer Michael Grabow - Executive Vice President and Chief Financial Officer Nora Brennan - Executive Vice President and Chief Financial Officer Erin Miller - Senior Vice President Sales and Marketing Conference Call Participants Maury Raycroft - Jefferies Edward White - H.C. Wainwright Reni Bennett Benjamin - JMP Securities Prakhar Agarwal - Cantor Fitzgerald Operator Good day and thank you for standing by.

Spectrum Pharmaceuticals, Inc. (SPPI) Q4 2022 Earnings Call Transcript

Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 33.33% and 5.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Spectrum Pharmaceuticals (SPPI) Reports Q4 Loss, Tops Revenue Estimates

BOSTON--(BUSINESS WIRE)--Spectrum Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Corporate Update

Spectrum Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Corporate Update

BOSTON--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the fourth quarter and full year 2022 financial results and provide a corporate update on Wednesday, March 22, 2023, at 8:30 a.m. Eastern/5:30 a.m. Pacific. Conference Call and Webcast: Wednesday, March 22, 2023 @ 8:30 a.m. Eastern/5:30 a.m.

Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update

SelectQuote

Zhihu

Use these tips for taking profits with penny stocks The post How to Take Profits With Penny Stocks  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Take Profits With Penny Stocks

Boxlight

Grove Collaborative Holdings

Imperial Petroleum

IronNet

Troika Media Group

VIQ Solutions

Virax Biolabs Group Ltd

GeneDx Holdings Corp

Wearable Devices Ltd

Penny stocks under $1 to watch this month. The post 10 Top Penny Stocks Under $1 To Watch For February 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks Under $1 To Watch For February 2023

BOSTON--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that a permanent J-code, J1449, has been issued for ROLVEDON (eflapegrastim-xnst) Injection by the U.S. Centers for Medicare & Medicaid Services (CMS) effective as of April 1, 2023. “This is an important milestone in the ROLVEDON launch.

Spectrum Pharmaceuticals Receives Permanent J-Code for ROLVEDON™ (eflapegrastim-xnst) Injection (J1449) from U.S. Centers for Medicare & Medicaid Services

LOS ANGELES--( BUSINESS WIRE )--The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. (“Spectrum” or “the Company”) (NASDAQ: SPPI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , Feb. 3, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI). To receive updates on the lawsuit, fill out the form: https://claimyourloss.com/securities/spectrum-pharmaceuticals-inc-loss-submission-form-2/?id=36157&from=4 This lawsuit is on behalf of all purchasers of Spectrum Pharmaceuticals, Inc. common stock during the period December 6, 2021 through September 22, 2022, inclusive.

SPPI SHAREHOLDER ALERT: Jakubowitz Law Reminds Spectrum Shareholders of a Lead Plaintiff Deadline of February 3, 2023

New York, New York--(Newsfile Corp. - February 2, 2023) - Levi & Korsinsky, LLP notifies investors in Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) of a class action securities lawsuit.The lawsuit on behalf of Spectrum investors has been commenced in the the United States District Court for the Southern District of New York. This lawsuit is on behalf of all purchasers of Spectrum Pharmaceuticals, Inc.

Spectrum Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 3, 2023 to Discuss Your Rights - SPPI

DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , Feb. 2, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Spectrum investors who were adversely affected by alleged securities fraud.

SPPI LAWSUIT ALERT: Levi & Korsinsky Notifies Spectrum Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Los Angeles, California--(Newsfile Corp. - February 1, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. ("Spectrum" or "the Company") (NASDAQ: SPPI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

FRIDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - January 31, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 6, 2021 and September 22, 2022, both dates inclusive (the "Class Period"), of the important February 3, 2023 lead plaintiff deadline.

SPPI FINAL DEADLINE FEBRUARY 3: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Friday Deadline in Securities Class Action - SPPI

Context Therapeutics LLC

Intelligent Bio Solutions Inc

Rent the Runway

Silo Pharma Inc

Sonoma Pharmaceuticals

Penny Stocks With News Light Up The Scanners This Week This week

7 Top Penny Stocks To Watch With Big News This Week

Los Angeles, California--(Newsfile Corp. - January 31, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. ("Spectrum" or "the Company") (NASDAQ: SPPI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

FRIDAY DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

BOSTON--( BUSINESS WIRE )--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology, today announced business highlights and preliminary ROLVEDON net sales for the quarter and year ended December 31, 2022.

Spectrum Pharmaceuticals Provides Update on ROLVEDON™ (eflapegrastim-xnst) Injection and Announces Unaudited Fourth Quarter 2022 Financial Results

NEW YORK , Jan. 31, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) alleging that the Company violated federal securities laws. This lawsuit is on behalf of all purchasers of Spectrum Pharmaceuticals, Inc. common stock during the period December 6, 2021 through September 22, 2022, inclusive.Lead Plaintiff Deadline: February 3, 2023 No obligation or cost to you.

SPPI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 3, 2023 in the Class Action Filed on Behalf of Spectrum Pharmaceuticals, Inc. Shareholders

NEW YORK , Jan. 30, 2023 /PRNewswire/ -- Attention Spectrum Pharmaceuticals, Inc. ("Spectrum") (NASDAQ: SPPI) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of all purchasers of Spectrum Pharmaceuticals, Inc. common stock during the period December 6, 2021 through September 22, 2022, inclusive.

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Spectrum Investors of a Lead Plaintiff Deadline of February 3, 2023

New York, New York--(Newsfile Corp. - January 29, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 6, 2021 and September 22, 2022, both dates inclusive (the "Class Period"), of the important February 3, 2023 lead plaintiff deadline.

SPPI DEADLINE: ROSEN, A RANKED AND LEADING FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPPI

NEW YORK , Jan. 27, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 22-cv-10677, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired If you are a shareholder who purchased or otherwise acquired Spectrum securities during the Class Period, you have until February 3, 2023 to ask the Court to appoint you as Lead Plaintiff for the class.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Pharmaceuticals, Inc. of Class Acton Lawsuit and Upcoming Deadline - SPPI

New York, New York--(Newsfile Corp. - January 27, 2023) - Levi & Korsinsky, LLP notifies investors in Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) of a class action securities lawsuit.The lawsuit on behalf of Spectrum investors has been commenced in the the United States District Court for the Southern District of New York. This lawsuit is on behalf of all purchasers of Spectrum Pharmaceuticals, Inc.

News for Spectrum Pharma Stock (SPPI)